Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Business Impact

Dealflow: Funding of Innovative Startups

Osiris Therapeutics, Miasole, PicoChip, and more

Company Spotlight
Miasol
  Several solar startups with innovative new technologies, including Nanosolar and Konarka, have recently received venture-capital funding. Miasolis looking to make solar power cost-effective by using thin-film manufacturing techniques, avoiding the expensive processing that silicon-based solar cells require.

Miasol enjoys great buzz thanks to a $16 million investment from the superstar VC firm Kleiner, Perkins. However, its competitor Nanosolar has also recently raised $20 million. It remains to be seen whether these new types of solar cells are generating investments based on the general promise of cleaner energy or whether they are commercially feasible technologies able to compete with existing and well-entrenched silicon-based photovoltaics.

Osiris Therapeutics  Amid all the debate over embryonic-stem-cell research, Osiris Therapeutics has been advancing the development of adult-stem-cell therapies. By using stem cells extracted from the bone marrow of living adults, Osiris has dodged the criticism that it is unethical to harvest cells from embryos.

This story is part of our September 2005 Issue
See the rest of the issue
Subscribe

Some Osiris products are already undergoing human tests. The first treatment for bone marrow transplant complications in leukemia patients is in phase II clinical trials and is the only stem-cell product with U.S. Food and Drug Administration fast-track status, according to Osiris. Two other products are also ready for human trials. One, designed to heal heart muscle damage in heart-attack patients, is in phase I clinical trials, and another, which will help repair knee tissue, recently won FDA approval to begin clinical trials.

While it is generally accepted by scientists that embryonic stem cells will have broader therapeutic applications, adult stem cells could also play a valuable role in repairing some types of tissue, and Osiris’s approach seems to be working. The company believes that, if all goes according to plan, its first therapeutic product may be available by 2007. 

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.

Subscribe today

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Business Impact

How technology advances are changing the economy and providing new opportunities in many industries.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

    Bimonthly digital/PDF edition

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special interest publications

    Discount to MIT Technology Review events

    Special discounts to select partner offerings

    Ad-free web experience

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.